Full metadata record
DC FieldValueLanguage
dc.creatorMorales-Lozano, M. I. (Mª Isabel)-
dc.creatorViering, O. (Oliver)-
dc.creatorSamnick, S. (Samuel)-
dc.creatorRodriguez-Otero, P. (Paula)-
dc.creatorBuck, A.K. (Andreas K.)-
dc.creatorMarcos-Jubilar, M. (María)-
dc.creatorRasche, L. (Leo)-
dc.creatorPrieto, E. (Elena)-
dc.creatorKortüm, K.M. (K. Martin)-
dc.creatorSan-Miguel, J.F. (Jesús F.)-
dc.creatorGarcia-Velloso, M. J. (María José)-
dc.creatorLapa, C. (Constantin)-
dc.identifier.citationMorales-Lozano, M. I. (Mª Isabel); Viering, O. (Oliver); Samnick, S. (Samuel); et al. "18F-FDG and 11C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers". Cancers. 12 (4), 2020,1042es_ES
dc.description.abstract11C-methionine (11C-MET) is a new positron emission tomography (PET) tracer for the assessment of disease activity in multiple myeloma (MM) patients, with preliminary data suggesting higher sensitivity and specificity than 18F-fluorodeoxyglucose (18F-FDG). However, the value of tumor burden biomarkers has yet to be investigated. Our goals were to corroborate the superiority of 11C-MET for MM staging and to compare its suitability for the assessment of metabolic tumor burden biomarkers in comparison to 18F-FDG. Twenty-two patients with newly diagnosed, treatment-naïve symptomatic MM who had undergone 11C-MET and 18F-FDG PET/CT were evaluated. Standardized uptake values (SUV) were determined and compared with total metabolic tumor volume (TMTV) for both tracers: total lesion glycolysis (TLG) and total lesion 11C-MET uptake (TLMU). PET-derived values were compared to Revised International Staging System (R-ISS), cytogenetic, and serologic MM markers such as M component, beta 2 microglobulin (B2M), serum free light chains (FLC), albumin, and lactate dehydrogenase (LDH). In 11 patients (50%), 11C-MET detected more focal lesions (FL) than FDG (p < 0.01). SUVmax, SUVmean, SUVpeak, TMTV, and TLMU were also significantly higher in 11C-MET than in 18F-FDG (p < 0.05, respectively). 11C-MET PET biomarkers had a better correlation with tumor burden (bone marrow plasma cell infiltration, M component; p < 0.05 versus p = n.s. respectively). This pilot study suggests that 11C-MET PET/CT is a more sensitive marker for the assessment of myeloma tumor burden than 18F-FDG. Its implications for prognosis evaluation need further investigation.es_ES
dc.description.sponsorshipThis research was funded by the Ministry of Economy and Competitiveness (PI 16/00225), the Ministry of Science and Innovation, Government of Spain (grant no. ADE 10/00028) and the Wilhelm Sander-Stiftung (grant 2017.061.1).es_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/Proyectos de investigación en salud (Modalidad Proyectos de investigación en salud) (AE Salud 2016)/PI16%2F00225/ES/Evaluación de 18F-FDG, 11C-MET y 11C-COL para la detección de infiltración tumoral en Mieloma Múltiple (MM): Estudio traslacional en modelos preclínico y clínico en pacientes (MIELOMAPET)es_ES
dc.subjectMultiple myelomaes_ES
dc.subjectTotal lesion glycolysis (TLG)es_ES
dc.subjectMetabolic tumor volume (MTV)es_ES
dc.subjectTotal lesion methionine uptake (TLMU)es_ES
dc.title18F-FDG and 11C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkerses_ES
dc.description.noteThis article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).es_ES

Files in This Item:
3.92 MB
Adobe PDF

Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.